Imaging Center COE

A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor

Oliver Sartor joins Charles Ryan to talk about the VISION trial, a trial testing the PSMA-617 agent, The novel therapeutic drug 177 Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The primary objective of this study is to compare the 2 alternative e...

Advantages of PSMA PET in APC Imaging Presentation - Stefano Fanti

At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 meeting, Stefano Fanti presented the advantages of PSMA PET-CT in advanced prostate cancer imaging. He highlighted the role of PSMA PET-CT in staging, biochemical recurrence, and therapy planning. Biography: Stefano Fanti, MD, Professor, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, Director of Nuclear Medic...

PSMA PET CT, A Mixed Blessing - Interview with Ian Davis

Professor Ian Davis joins Carmel Pezaro to discuss the pitfalls of PSMA PET CT scans at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Starting the discussion on the disadvantages of PSMA PET, Professor Davis refers to PSMA PET as a bit of a mixed blessing and the challenge being the amount of enthusiasm for it and trying to bring it into clinical practice in a meaningful way. Wit...

Gold Nanoparticles Used in Photothermal Therapy for Prostate Tumors- Art Rastinehad

(Length of Interview: 14 min) John Fortin interviews Art Rastinehad on a new publication published in the Proceedings of the National Academy of Science on prostate cancer and nanomedicine. Art Rastinehad and colleagues at Icahn Scool of Medicine at Mount Sinai are the first to perform human trials using nanoshell directed photothermal ablation. In this podcast interview, Dr. Rastinehad reports th...

PSMA Targeted Therapies Presentation - Michael Hofman

Professor Michael Hofman presented on prostate-specific membrane antigen (PSMA) targeted therapies during the Management of castration-resistant prostate cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, presenting data from both of his groups in Australia. Dr. Hofman highlights the progress of a single-centre, single-arm, phase 2 study; [177Lu]-PSMA-617 radi...

Imaging Bone (Flare) Responses in Advanced Prostate Cancer Presentation - Anwar Padhani

Anwar Padhani presents at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 on imaging and flare responses when assessing patients with metastatic castration-resistant prostate cancer (mCRPC). In his presentation, Dr. Padhani notes that bone scans/CT scans lead to poor confidence for knowing the true clinical states and assessing therapy benefits for bone disease in advanced prostate...

Credentialing Imaging as an Outcome Measure in Prostate Cancer - Lawrence H. Schwartz and Michael J. Morris

Michael Morris, MD, and Larry (Lawrence) Schwartz joins Charles Ryan, MD in a conversation about credentialing imaging as an outcome measure in prostate cancer and its impact in clinical trials. They focus on the following questions: How do we credential images? How do we perform them? And how do we interpret them? Their conversation also focuses on determining progression-free survival (PFS) from...

SNMMI Osseous Scintigraphy - Ephraim E. Parent

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) presents the Prostate Cancer Imaging and Therapy curriculum. In this continuing education session, Dr. Ephraim Parent joins Dr. Phil Koo to present and discuss bone imaging and the role in prostate cancer, specifically bone scintigraphy. His presentation outlines an overview of Radiopharmaceuticals that are used for bone imaging, planar...

Case-based Approaches: PSMA and Personalized Prostate Cancer Care - Frankis Almaguel

Frankis Almaguel, MD joins Phillip Koo, MD for the ongoing lecture series that is sponsored by the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Dr. Almaguel speaks to therapeutic interventions based on Prostate-specific membrane antigen (PSMA) findings that have the potential of changing the treatment of prostate cancer and the impact of personalized care in this disease space. Frank...

Bombesin - A New Frontier for Prostate Cancer Imaging - Andrei Iagaru

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) presents the Prostate Cancer Imaging and Therapy curriculum. Dr. Andrei Iagaru presents the state of development of Gastrin-Releasing Peptide Receptors as Targets for Imaging in Prostate Cancer. He and Phil Koo, MD then discuss the clinical development of Bombesin in the imaging of prostate cancer. Biographies: Andrei H. Iagaru, MD, FAC...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.